The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Roche’s Hemlibra, fast-tracking its development and review for the treatment of haemophilia A without factor VIII inhibitors.

Hemlibra is a prophylactic, subcutaneous, once-a-week drug formulated to combine the factor IXa and factor X to trigger coagulation cascade and restore blood clotting in haemophilia A.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The FDA previously granted similar status to Hemlibra in September 2015 for routine prophylaxis of bleeding episodes in adults and children with haemophilia A characterised by factor VIII inhibitors.

Hemlibra received complete regulatory approval in November last year.

“Hemlibra is the first medicine to show superior efficacy compared to factor VIII prophylaxis, the standard of care for people with haemophilia A without inhibitors.”

Roche chief medical officer and global product development head Sandra Horning said: “Hemlibra is the first medicine to show superior efficacy compared to factor VIII prophylaxis, the standard of care for people with haemophilia A without inhibitors, in an intra-patient comparison.

“We look forward to working with health authorities to make Hemlibra available to people without inhibitors as soon as possible, and we are excited to share this news with the community as we join in celebrating World Hemophilia Day.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest FDA decision comes after a review of findings from the Phase III HAVEN 3 trial where the drug demonstrated a statistically significant and clinically meaningful decrease in treated bleeds in subjects aged 12 or above when compared to no prophylaxis.

It was observed that once-weekly Hemlibra prophylaxis was superior to previous factor VIII.

Hemlibra also secured approvals in other international markets for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.